Clinical Trial: Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer

U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07745322) titled 'Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer' on July 30.

Brief Summary: The intratumoral microbiota is a key modulator of the tumor immune microenvironment. This study aims to clinically validate a novel, AI-driven digital pathology biomarker-the Microbial-Sensory Coupling (MSC) index-which measures the spatial proximity between the intratumoral bacterium Campylobacter gracilis(C. gracilis) and host Trace Amine-Associated Receptor 1 (TAAR1)+ tumor cells. The study will evaluate whether the MSC index, measured in pre-treatment tumor biopsy tissues, can accurately predict clinical responsiveness and surviva...